首页> 美国卫生研究院文献>Bioscience and Microflora >Intestinal Microbiota and Health in Childhood
【2h】

Intestinal Microbiota and Health in Childhood

机译:肠道菌群与儿童健康

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Western medicine has only recently discovered that the intestinal microbiota is a major determinant of the well-being of the host. Although it would be oversimplifying to limit the benefits of breastfeeding compared to cow milk based infant formula to differences in gastrointestinal flora, the impact of the latter has been demonstrated beyond doubt. As a consequence, gastro intestinal flora manipulation with pre- and probiotics added to infant formula or food (mainly milk based products) and/or with food supplements have become a priority area of high quality research. The composition of intestinal microbiota can be manipulated with “biotics”: antibiotics, prebiotics and probiotics. Commercialised pre- and probiotic products differ in composition and dose. Major threats to the concept of developing a major role for intestinal microbiota manipulation on health are the commercialisation of products claiming health benefits that have not been validated. Legislation of food supplements and medication differs substantially and allows commercialisation of poor quality food supplements, what will result in negative experiences. Medicinal products can only be advertised for which there is scientific proof of benefit that has been demonstrated with “the same product with the same dose in the same indication”. Specificity of prebiotics and probiotics strains and product specificity are of importance, although high quality evidence for this assertion is missing.Dose-efficacy studies are urgently needed. Probiotics are “generally regarded as safe”,but side effects such as septicemia and fungemia have sometimes been reported in high-risksituations.
机译:西医直到最近才发现肠道菌群是宿主健康的主要决定因素。尽管将母乳喂养的益处与基于母乳的婴儿配方相比限制在胃肠道菌群的差异上过于简单了,但毫无疑问地证明了后者的影响。因此,在婴儿配方食品或食物(主要是牛奶产品)中添加益生菌和益生菌和/或在食物补充剂中进行肠道菌群操纵已成为高质量研究的优先领域。肠道菌群的组成可以通过“生物”来操纵:抗生素,益生元和益生菌。商业化的益生菌和益生菌产品的成分和剂量不同。在肠道菌群操纵对健康发展中起主要作用的概念的主要威胁是声称其健康益处尚未得到证实的产品的商业化。食品补充剂和药物的立法有很大不同,并且允许劣质食品补充剂的商业化,这将带来负面的体验。只能在有科学依据的药品广告中进行宣传,“具有相同剂量,相同适应症的相同产品”已证明了这种有益效果。益生菌和益生菌菌株的特异性以及产品的特异性很重要,尽管缺少这种说法的高质量证据。迫切需要剂量效率研究。益生菌“通常被认为是安全的”,但是据报道,高危人群有时会出现诸如败血病和真菌病等副作用情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号